Mesothelioma trial suggests immunotherapy as an alternative to chemotherapy
Patients with mesothelioma may gain similar benefit from immunotherapy as chemotherapy, and good responders may provide important clues to novel treatment for the thousands of new cases each year. New data highlight the need to understand the biological mechanisms whereby mesothelioma, which is incurable, adapts to immunotherapy in some patients but not in others, resulting in variations in treatment response.
To discuss more details regarding this topic- join us at Vienna,Austria:
European Summit on Pharmacology and Toxicology
Thanks & Regards,
Bommali S
Scientific Event Manager | Pharmacology Congress 2020 | Longdom Conferences
LONGDOM GROUP SA |Avenue Roger Vandendriessche, 18, 1150 Brussels, Belgium
Toll-Free: +32 800-753-58
LONGDOM GROUP SA |Avenue Roger Vandendriessche, 18, 1150 Brussels, Belgium
Toll-Free: +32 800-753-58
Email: pharmacology2020@outlook.be | ESPT2020@outlook.be
No comments:
Post a Comment